Zita-Met Plus 20mg/500mg Tablet ER is a combination oral antidiabetic medication containing Metformin hydrochloride 500mg and Teneligliptin 20mg, formulated as an extended-release tablet. It is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic control. Metformin primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby reducing fasting and postprandial blood glucose levels. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by prolonging the action of glucagon-like peptide-1 (GLP-1), which increases insulin secretion and suppresses glucagon release in a glucose-dependent manner. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma concentrations. Zita-Met Plus is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination offers a complementary mechanism of action, providing effective glycemic control with a reduced risk of hypoglycemia.